Brokerages predict that Meridian Bioscience, Inc. (NASDAQ:VIVO) will report $0.16 earnings per share for the current quarter, Zacks reports. Three analysts have issued estimates for Meridian Bioscience’s earnings. Meridian Bioscience reported earnings per share of $0.15 in the same quarter last year, which would suggest a positive year-over-year growth rate of 6.7%. The firm is scheduled to announce its next earnings report before the market opens on Thursday, November 8th.
On average, analysts expect that Meridian Bioscience will report full-year earnings of $0.70 per share for the current financial year, with EPS estimates ranging from $0.70 to $0.71. For the next year, analysts forecast that the company will post earnings of $0.77 per share, with EPS estimates ranging from $0.74 to $0.81. Zacks’ EPS calculations are a mean average based on a survey of sell-side analysts that follow Meridian Bioscience.
Several research analysts have weighed in on the company. BidaskClub lowered Meridian Bioscience from a “hold” rating to a “sell” rating in a report on Thursday, October 4th. ValuEngine upgraded Meridian Bioscience from a “hold” rating to a “buy” rating in a report on Monday, October 29th. One investment analyst has rated the stock with a hold rating and three have issued a buy rating to the company’s stock. The stock has an average rating of “Buy” and an average target price of $16.00.
VIVO stock opened at $16.48 on Friday. The company has a debt-to-equity ratio of 0.27, a quick ratio of 3.89 and a current ratio of 5.73. The stock has a market cap of $697.83 million, a price-to-earnings ratio of 24.60 and a beta of 0.54. Meridian Bioscience has a 1-year low of $13.53 and a 1-year high of $17.10.
In other Meridian Bioscience news, Director John Mcilwraith bought 2,000 shares of Meridian Bioscience stock in a transaction on Friday, August 24th. The shares were purchased at an average cost of $15.63 per share, for a total transaction of $31,260.00. Following the completion of the acquisition, the director now owns 6,000 shares in the company, valued at approximately $93,780. The acquisition was disclosed in a document filed with the SEC, which is accessible through this link. Insiders own 2.70% of the company’s stock.
Several institutional investors have recently modified their holdings of VIVO. BlackRock Inc. lifted its holdings in shares of Meridian Bioscience by 9.6% in the second quarter. BlackRock Inc. now owns 5,901,032 shares of the company’s stock valued at $93,827,000 after purchasing an additional 518,731 shares in the last quarter. Assenagon Asset Management S.A. bought a new stake in shares of Meridian Bioscience in the third quarter valued at about $4,301,000. Renaissance Technologies LLC lifted its holdings in shares of Meridian Bioscience by 9.1% in the second quarter. Renaissance Technologies LLC now owns 2,631,276 shares of the company’s stock valued at $41,837,000 after purchasing an additional 220,500 shares in the last quarter. Segall Bryant & Hamill LLC bought a new stake in shares of Meridian Bioscience in the second quarter valued at about $3,369,000. Finally, Systematic Financial Management LP lifted its holdings in shares of Meridian Bioscience by 11.3% in the second quarter. Systematic Financial Management LP now owns 1,131,715 shares of the company’s stock valued at $17,994,000 after purchasing an additional 114,687 shares in the last quarter. Institutional investors own 88.56% of the company’s stock.
About Meridian Bioscience
Meridian Bioscience, Inc, a life science company, develops, manufactures, distributes, and sells diagnostic test kits primarily for various gastrointestinal and viral diseases, respiratory and parasitic infectious diseases, and elevated blood lead levels worldwide. The company operates through Diagnostics and Life Science segments.
Featured Article: Technical Analysis of Stocks and What It Means
Get a free copy of the Zacks research report on Meridian Bioscience (VIVO)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Meridian Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Meridian Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.